ERBB2 and breast carcinoma: As a model system, we chose HerceptinTM (trastuzumab), a well characterized antibody therapy for HER2-overexpressing breast carcinoma, because HER2-overexpression is correlated with a poor prognosis and an increased incidence of CNS metastases [10].